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Abstract
Background: During the last decades, many basic and clinical research have pointed to the role
of B vitamins (folate, vitamins B6 and B12) and n-3 fatty acids as nutritional factors that might have
a protective effect on the development of cardiovascular diseases (CVD).
Methods/design: The SU.FOL.OM3 (SUpplementation with FOlate, vitamin B6 and B12 and/or
OMega-3 fatty acids) trial is a randomized double-blind, placebo-controlled, secondary-prevention
trial designed to test the efficacy of 5-methyl tetra-hydro-folates (5-MTHF) supplementation, in
combination with vitamin B6 and B12 and/or n-3 fatty acids, at nutritional doses, on fatal and non
fatal ischemic CVD in a 2 × 2 factorial design. A total of 2501 patients aged between 45 and 80
years who had a past history, in the previous year, of myocardial infarction (n = 1151) or instable
angina pectoris (n = 711) or an ischemic stroke (n = 639) were included. Subjects have to be
supplemented and followed up for five years. Daily supplementation comprised nutritional doses
of 5-MTHF (560 μg), vitamin B6 (3 mg) and B12 (20 μg) and/or n-3 fatty acids (600 mg with an
EPA:DHA ratio of 2:1). A factorial design 2 × 2 has been applied to investigate the separate effects
of the B-vitamins, and the n-3 fatty acids, as well as their interaction as compared to the placebo.
The primary endpoint is a combination of myocardial infarction, ischemic stroke and cardiovascular
death. Secondary endpoints are events of the composite endpoint taken separately, total mortality,
and other cardiovascular events such as acute coronary syndromes, coronary revascularization,
cardiac failure, arrhythmia...
Conclusion: Baseline socio-demographic and medical characteristics of participants are totally
comparable in the four randomized groups.
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During the last decades, many basic and clinical research
have pointed to the role of B vitamins (folate, vitamins B6
and B12) and n-3 fatty acids as nutritional factors that
they might have a protective effect on the development of
cardiovascular diseases.
The interest for B-vitamins is linked to the "homocysteine-
hypothesis" of vascular disease [1,2]. Elevated plasma
homocysteine levels have been related to a higher risk for
coronary heart disease (CHD) and stroke, and homo-
cysteine has been demonstrated to be lowered by folic
acid and vitamin B12 supplementation [3], raising the
prospect that adequate intake of B-vitamins could
decrease the risk of CHD and stroke [4]. Several meta-
analyses of prospective cohort studies evidenced that,
after taking into account known risk factors, a lower
homocysteine level was associated with a lower risk of
CHD and a lower stroke risk [5-7].
Omega-3 fatty acids are thought to prevent cardiovascular
diseases by their role in lowering levels of serum lipid [8],
and by their anti-inflammatory, antithrombotic, anti-
plateled-derived growth factor and antiarrhythmic prop-
erties. Several epidemiological studies from many coun-
tries suggested that an increased intake of dietary fish or
fish oil rich in long-chain polyunsaturated n-3 fatty acids
(PUFAs), eicosapentanoic acid (EPA) and docosahexae-
noic acid (DHA), could decrease the incidence of cardio-
vascular diseases [9-13].
However, for B-vitamins as for n-3 fatty acids, epidemio-
logical studies are mainly observational, which do not
permit to conclude on a direct causal link between these
nutrients and the risk of cardio and cerebrovascular dis-
eases. Few years ago, some randomized trials have been
launched to assess the effects of folate or n-3 fatty acids on
cardiovascular outcome. Several CVD prevention large-
scale B-vitamin supplementation trials were designed and
initiated in the mid 1990's. The results of first of these
large randomized trials has not provided clear evidence of
any beneficial effect on CVD risk of lowering homo-
cysteine concentration [14-17]. Possible reasons for the
failure of these initial trials to demonstrate a beneficial
effect might include: an inadequate number of partici-
pants, an insufficient duration of treatment, a reduction in
the effect of B-vitamins by folic acid fortification; and
finally, the true absence of effect on vascular risk. In retro-
spect, few of the completed homocysteine-lowering trials
had sufficient statistical power to assess the predicted dif-
ferences in risk suggested by the observational epidemio-
logical studies. One of the possible reasons is that most of
these trials were conducted in a country where folic acid-
enriched flour is being compulsory. The consequence is a
population-based homocysteine lowering effect and a
potential power shortage of the above trials [15,17].
Regarding the effects of n-3 fatty acids on CVD outcomes,
the totality of the data currently available suffered from
limitations that make drawing firm conclusions difficult
[18-20]. Indeed, the evidence to support cardiovascular
benefits from n-3 PUFA intakes in patients with past his-
tory of cardiovascular diseases came from only one large
randomized control trial (RCT) [21]. In some other trials,
inconsistent antiarrhythmic effects and no significant
overall effect on mortality have been observed in different
types of patients with cardiovascular diseases [22-24].
Moreover, most of the available trials do not permit to
conclude on the effects of specific fatty acids (25). Conver-
gence of well-designed large RCTs that assess the effects of
EPA and DHA on CVD outcomes with long follow-up
periods, in different context are needed to conclude.
Finally, definitive evidence that supplementation with B-
vitamins or n-3 fatty acids will lead to a reduced cardio-
vascular diseases morbidity and/or mortality is still scarce
[25].
Taken all this information together, there was a need for a
large double-blind placebo controlled randomized inter-
vention trial evaluating the efficacy of supplementation
with B-vitamins and n-3 fatty acids in nutritional doses
with hard cardiovascular endpoints. Therefore, we
decided to launch the SU.FOL.OM3 study (SUpplementa-
tion with FOlate, vitamin B6 and B12 and/or OMega-3
fatty acids) a secondary intervention trial designed to test
the efficacy of daily supplementation with 5-methyl-THF/
vitamin B12/B6 and/or n-3 polyunsatured fatty acids to
prevent fatal and non fatal coronary heart disease and
stroke. The present report describes design, implementa-
tion and baseline characteristics of participants of this 5-
year cohort study, which started in 2003 in France.
Study design
The SU.FOL.OM3 study is a double-blind randomized
placebo-controlled secondary intervention trial in which
participants are supplemented daily for a period of 5 years
with nutritional doses of 5-methyl-THF (560 μg), vitamin
B6 (3 mg) and B12 (20 μg) and/or n-3 fatty acids supple-
ments (600 mg with an EPA:DHA ratio of 2:1). A 2 × 2 fac-
torial design has been used to investigate the separate
effects of the B-vitamins (S1), and the n-3 fatty acids (S2)
as well as their interaction. B-vitamins placebo (P1) and
omega-3 fatty acid placebo (P2) pills have been devel-
oped to respct the blindness of the trial. Participants have
been randomly allocated to the following treatment
groups: 5-methyl THF, vitamin B6 and B12 and a "omega-
3 fatty acid placebo" (S1P2); n-3 fatty acids and a "5-
methyl THF, vitamin B6 and B12 placebo" (S2P1); 5-Page 2 of 9
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(S1S2); the two placebos (P1P2).
The primary objective of this experimental epidemiologi-
cal study is to test the hypothesis that supplementation
with 5-methyl THF, vitamin B6 and B12 and/or omega-3
fatty acids prevents death from cardiovascular causes,
recurrence of ischemic events in patients who already
have experienced a coronary or cerebrovascular event. Sec-
ondary objectives are to prevent death for any cause and
hospitalization for events of the composite endpoint
taken separately and other cardiovascular events.
The protocole has been approved by the ethical commit-
tee for studies with human subjects named the "Comité
Consultatif pour la Protection des Personnes se prêtant à
la Recherche Biomédicale" (CCPPRB n° 1933) of Paris-
Cochin, and the "Comité National Informatique et Lib-
erté" (CNIL n° 901230) for keeping all medical informa-
tion confidential and anonymous. All patients provided
written informed consent.
Population, sampling
The study cohort involves patients with a history of cardi-
ovascular diseases recruited from all around France.
Estimation of sample size and length of follow up were
based on models including the specification of the inci-
dence of the trial outcomes in France (incidence of cardio
and cerebro-vascular disease in secondary prevention),
estimated adherence to taking the supplement capsules,
rate of loss to follow-up and statistical parameters. Our
goal is to be able to detect relatively weak effects with an
alpha risk of 5 % and a power of 90%, testing a one-sided
effect. Even if we will check an interaction between B-vita-
mins and n-3 fatty acids, a priori, we do not expect such
an interaction and therefore we will not take it into
account while estimating the sample size.
Risk reduction in each group
Our hypothesis is to observe a risk reduction of fatal and
non fatal coronary and cerebrovascular events due to each
intervention of 10%, equivalent to a risk ratio of 0.9 in
group S1P2 and S2P1 and a risk of 0.81 in group S1S2 as
compared to the risk of the P1P2 group.
Baseline risks in each group
The baseline risk of the P1P2 group was estimated to
0.087. The baseline risk of the S1P and S2P group is thus
expected 0.078 (0.087 × 0.9).
Risk reduction in combined groups
To estimate the effect of S1 we will compare the combined
group S1P2 and S1S2 with the combined group P1P2 and
S2P1. The risk reduction in group S1P2 and S1S2 is thus
estimated at 14.5% ([10% in group S1P2 and 19% in
group S1S2]/2).
Baseline risk in combined groups
The baseline risk in group P1P2 and S2P1 is: 0.0826 (=
[0.078 + 0.087]/2). To estimate the effect of S2 we will
compare group S2P1 and S1S2 with group P1P2 and
S1P2, the baseline risk in group P1P2 and S1P2 is also:
0.0826 (= [0.078 + 0.087]/2).
For the calculation of the necessary number of patients we
have taken into account the comparison of exponential
survival distributions, and a follow up of 5 years for each
included subjects. With these parameters we calculated
that a number of 1188 subjects are necessary in each com-
bined group, for a total of 2376 patients. Taking into
account possible dropout, we aim at including 2500 sub-
jects in the trial.
Recruitment and follow-up
First recruitment of subjects have been done through a
network of 392 cardiologists and neurologists, all around
France, working either in general hospitals, independently
or in rehabilitation centers.
Follow-up time was defined by the time from the baseline
visit until the first event date (for those who had an
event); patients without event will be censored at the end
of follow-up.
Clinicians had the responsibility to give potential study
participants (i.e. patients that meet the eligibility criteria)
the first information about the study protocol. They
explained that participation included taking daily freely
provided supplements. In addition, they explained that
25% of all participants received a complete placebo treat-
ment. The clinicians also explained that despite the fact
that they might receive only placebo, all participants ben-
efit from a free annual biological check-up.
The clinicians offered a short questionnaire to all patients
willing to participate. The questionnaire asked for 1)
information by which inclusion of patients was checked,
2) the patients address and 3) permission to give the ques-
tionnaire's information to the SU.FOL.OM3 team. Once
the clinicians have obtained a completed questionnaire
from potential participants, the SU.FOL.OM3 team con-
tacted the patient in order to verify his/her eligibility, to
collect demographic, life-style and present and past health
informations and to arrange an appointment.
Then patients were randomly assigned to a treatment
group by means of a computerized system. The randomi-
zation was stratified for age in 3 classes (44–54, 55–64,
65–80), sex, and the type of pathologies at enrolment andPage 3 of 9
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they underwent a yearly visit and received their supple-
mentation (enough for 1 year) in a package carrying their
identification number.
Inclusion criteria
The participants should be 45 – 80 years at baseline. Par-
ticipants should have experienced a coronary or cerebral
ischemic acute event 1 to 12 months before inclusion. A
coronary or cerebral event was defined as: 1) myocardial
infarction; 2) coronary syndrome without myocardial inf-
arction; 3) an ischemic cerebral vascular accident.
- To fulfill the cerebrovascular disease criteria, the patients
must have had a previous documented ischemic stroke
(classical clinical criteria plus cerebral imaging: computed
tomography or magnetic resonance imaging) with a
Rankin [26] score < 3 at 3 months (ICD-10 codes: I63.0–
I63.9). Transient ischemic attack does not represent an
inclusion criteria.
- To fulfill the coronary acute event criteria [27], the
patients must have had either a previous documented
myocardial infarction (ICD-10 codes: I21.0–I21.9),
defined by at least 2 of the following :
 Typical chest pain,
 Electrocardiographic modifications related to myocar-
dial infarction,
 Cardiac enzymes increase
Or an acute coronary syndrome without myocardial inf-
arction (ICD-10 codes: I20.0–I20.1), defined by the 2 of
the 3 following criteria:
 Typical chest pain;
 Electrocardiographic modifications related to acute cor-
onary syndrome or coronary artery disease documented in
the management of the acute coronary syndrome with an
angiographic coronary stenosis over 50%;
 Evidence-based previous coronary artery disease defined
by previous angina pectoris (chest pain precipitated by
exertion and relieved by rest or nitrates) confirmed by cor-
onary angiography or a positive exercise test, previous
myocardial infarction, typical sequelae on electrocardiog-
raphy, previous coronary percutaneous transluminal angi-
oplasty, and/or previous coronary bypass surgery.
Were not included:
- patients that are incapable of understanding the study
protocol or who refuse to sign the informed consent;
- patients with a pathology that might interfere with
homocysteine or omega-3 fatty acid metabolism, in par-
ticular those that use methotrexate for the treatment of a
cancer or rheumatoid arthritis;
- chronic renal failure (plasma level of creatinine > 200
μmol/L or creatinine clearance < 40 ml/min);
- patients with a non-cardiovascular pathology with a sus-
pected survival time less than the 5 years period of the
study (solid cancer, evolved dementia, leukemia, etc.);
- patients taking treatment with B vitamins or omega-3
fatty acids.
Outcome
Fatal and non fatal cardiovascular events, and all causes
mortality were reported. Research assistants verified all
information by checking medical records, hospital dis-
charge forms, death certificates, and autopsy data. A cod-
ing form is used to classify all the cardiovascular events.
Two Medical Committees were established, comprising
epidemiologists, cardiologists, internists, pathologists
and neurologists. Members of these committees were una-
ware of study-group assignments. Their task was to pro-
vide a validation of cardiovascular and stroke events
during follow-up, in addition to mortality causes, accord-
ing to the International Classification of Diseases, 10th
edition (ICD-10) [28].
Deceased subjects were confirmed from the mortality
records of the Institut National de Statistiques et d'Etudes
Economiques. A patient of our cohort was considered to
be deceased when he had the same first name, last name,
sex, and date of birth as a person recorded in the Institut
National de Statistiques et d'Etudes Economiques mortal-
ity records during the period of follow-up. These data
were provided by the Department of Mortality of the Insti-
tut National de la Santé et de la Recherche Médicale
(INSERM).
Endpoints
The primary endpoint is the composite of the first major
cardiovascular event, which was defined as nonfatal myo-
cardial infarction (definition above), stroke (definition
above), or death from cardiovascular disease. Death from
cardiovascular cause was defined as:
- fatal myocardial infarction;
- fatal stroke, ischemic, hemorrhagic or of unknown etiol-
ogy;Page 4 of 9
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occurred within 1 h after the onset of acute symptoms,
with no evidence that violence or accident played any role
in the fatal outcome;
- fatal aortic dissection, fatal cardiac failure, and any fatal
event defined as from cardiovascular cause by the medical
committee.
Secondary endpoints
Secondary endpoints are events of the composite end-
point taken separately, total mortality, and other cardio-
vascular events:
- each component of the composite primary endpoint
taken isolately;
- acute coronary syndrome without myocardial infarction;
- resuscitate sudden death;
- coronary bypass surgery;
- percutaneous transluminal angioplasty;
- acute cardiac failure;
- ventricular arrhythmia;
- supra ventricular arrhythmia;
- any cardiac surgery;
- transient ischemic attack;
- deep vein thrombosis;
- pulmonary embolism;
- carotid surgery or carotid percutaneous transluminal
angioplasty;
- peripheral arterial surgery or percutaneous transluminal
angioplasty;
- any vascular procedure.
Treatment
Study supplements were given as 2 capsules per day. The
supplements were provided in a package containing 53
blisters of 2 × 7 capsules, each corresponding to one week
of both treatments.
It was planned that participants will betaking the supple-
ments for 5 consecutive years. At the first appointment
participants were given supplements for the first treat-
ment year. The supplements for the following 4 years will
be supplied each year during the annual clinical and bio-
logical check-up of the participants.
The supplements consist of soft gelatin capsules. These
capsules either contain the B-vitamins, the n-3, or the pla-
cebo substance. The placebo capsules look and taste iden-
tical to the active supplements. The raw material for the n-
3 capsules have been provided without charge by Pierre
Fabre, Merck Eprova AG provided the 5-methylTHF and
Roche Laboratory the B6 and B12-vitamins. The gelatin
capsules are manufactured by Catalent Pharma Solutions
(Beinheim, France; Swindon, UK). Packaging of the cap-
sules has been done under the responsibility of Klocke
(Weingarten, Germany). These sponsors were not
involved in the design, execution, analysis, or reporting in
the trial results.
Follow-up examination
Participants were given the standard therapy for their dis-
ease having led to the inclusion and each subject under-
went a yearly visit consisting in a physical and biological
monitoring check-up in 257 centers (hospitals or heath
centers). Every six months after enrollement, a question-
naire is mailed to each participant. Subjects were asked
about study outcomes (diseases, hospitalizations, etc.)
and compliance. Those who do not return the question-
naire were interviewed by telephone by dedicated study
physicians. Moreover, each year a simple follow-up ques-
tionnaire is mailed to to the participants allowing to col-
lect data on incident health events and on the evolution
of cardiovascular and lifestyle factors (smoking, dietary
habits, physical activity, etc.).
The general practioners or cardiolologists or neurologists
who follow the SU.FOL.OM3 subjects are requested to
report any relevant information on health-events of the
SU.FOL.OM3 patients.
In the blood that is drawn during the first appointment
(baseline: T0) the following parameters were determined
: total cholesterol, triglycerides, HDL-cholesterol, LDL-
cholesterol, fasting glucose were measured by enzymatic
method with the use of C8000 System Abbott (Rungis,
France); the fatty acid composition of plasma lipids was
determined by gas-chromatography, plasma homo-
cysteine, serum folate and vitamin B12 as well as RBC
folates were measured by a competitive immunoassay
with direct chemiluminescence detection, pyridoxal 5'-
phosphate (circulating form of vitamin B6) was deter-
mined in plasma by high-performance liquid chromatog-
raphy; the polymerase chain reactions for 677 C>T and
1298 C mutations in the gene encoding for MTHFR werePage 5 of 9
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respectively.
Each year, for the subsequent years approximately on the
anniversary date of baseline (T1, T2, T3, and T5), plasma
homocysteine, folate, vitamin B12 and pyridoxal phos-
phate concentrations, erythrocyte concentration of folate,
total cholesterol, triglycerides, HDL-cholesterol, LDL-cho-
lesterol, and fasting glucose were planned to be measured
for the whole sample and fatty acids profiles in a subsam-
ple. A biobank has been set up at baseline.
Participant characteristics at baseline
2501 patients were included in the SU.FOL.OM3 cohort
(1987 men and 514 women): age was 61.5 + 0.2 (m ± SD)
years for men and 63.7 + 0.4 years for women; 1151 par-
ticipants have experienced a myocardial infarction ; 711
an acute coronary syndrome without myocardial infarc-
tion and 639 an ischemic stroke.
X persons presented blood level for B-vitamins corre-
sponding as values observed in subjects taking B-vitamins
supplements or treatment. As this was an exclusion crite-
ria, those randomized subjects were considered in condi-
tion of protocol violation and were excluded for analysis.
Principal characteristics, at the start of intervention, of
participants contributing to analysis, are presented, for the
4 groups in Table 1.
Groups are comparable for all the studied characteristics.
Comments
The SU.FOL.OM3 Study was designed and initiated to test
the hypothesis that supplementation with a natural form
of folate (5-methyl-THF), a and/or n-3 fatty acids given in
a population of subjects with past history of cardio or cer-
ebro-vascular diseases might reduce fatal or non fatal
ischemic events.
Human observational epidemiological studies and exper-
imental works provide strong indication that n-3 PUFA,
by one hand, and B-vitamins, on the other hand, could
prevent cardiovascular diseases [29-32]. There are several
randomized double blind interventions, testing n-3 fatty
acids with available results or still on going. However, we
should point out that some of these studies involve a
small number of subjects; some of these studies has an
open intervention design and used unblended clinical
endpoint assessments. Some intervention trials with
mostly intermediate end-points did not have a study
design enabling a firm conclusion. Concerning trials with
n-3 fatty acids, some studies used global dietary interven-
Table 1: General characteristics of sample at baseline by group *
Intervention groups
A B C D
n 620 633 622 626
Age (years) 61.5 ± 9.3 61.4 ± 9.3 61.4 ± 8.7 61.4 ± 8.9
Gender
- Men (%) 492 (79.3) 501 (79.1) 497 (79.9) 497 (79.4)
- Women (%) 128 (20.7) 132 (20.9) 125 (20.1) 129 (20.6)
Inclusion criteria
- myocardial infarction (%) 279 (45.0) 301 (47.5) 288 (46.3) 283 (45.2)
- unstable angina (%) 176 (28.4) 184 (29.1) 168 (27.0) 183 (29.2)
- stroke (%) 165 (26.6) 148 (23.4) 166 (26.7) 160 (25.6)
Level of education (%)
Elementary school 374 (61.9) 364 (59.0) 369 (60.6) 376 (61.0)
Secondary school 138 (22.9) 145 (23.5) 151 (24.8) 136 (22.1)
University or equivalent 92 (15.2) 108 (17.5) 89 (14.6) 104 (16.9)
Smoking (%)
Current smokers 69 (11.4) 69 (11.3) 67 (11.0) 63 (10.2)
Former smokers 369 (61.2) 359 (58.8) 369 (60.7) 395 (63.7)
Non-smokers 165 (27.4) 183 (29.9) 172 (28.3) 162 (26.1)
Blood pressure (mm Hg)
systolic 133.1 ± 21.4 134.1 ± 21.9 133.5 ± 22.2 132.6 ± 20.0
diastolic 83.6 ± 13.2 84.0 ± 12.9 84.0 ± 13.7 82.6 ± 12.1
Body mass index (Kg/m2) 27.6 ± 4.4 27.5 ± 4.0 27.7 ± 4.0 27.5 ± 3.8
Waist/Hip ratio 0.95 ± 0.07 0.95 ± 0.07 0.95 ± 0.07 0.95 ± 0.08
* m ± SD, except if specifiedPage 6 of 9
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to n- 3 fatty acids. Even the large GISSI trial [21] was lim-
ited in that it did not use a placebo group but only a con-
trol group.
Secondary intervention trials with hard endpoints and B-
vitamin supplementation have been launched in the last
decade and first results do not provide clear evidence of
any beneficial effect on CVD risk of lowering homo-
cysteine concentration [14-17]. The hypothesis of differ-
ent beneficial effects of folic acid on coronary and
cerebrovascular prevention is still controversial. Indeed, a
recent meta analysis has shown that a cerebrovascular
protection effect was still associated with folic acid [33],
while another-one did not demonstrate any reduction in
cardiovascular risk [34]. Most of the previously published
randomised controlled trials in the scope of homo-
cysteine took place in regions where flour is fortified with
folic acid. Such a fortification decreases plasma levels of
homocysteine at the population level, and then, decreases
the expected beneficial cardiovascular effect of folic acid
supplementation. The decreased power of previous thera-
peutic trials could be an explanation for their negative
results. The SUFOLOM 3 trial takes place in a non fortified
zone, and the baseline relatively high levels of homo-
cysteine (14 μmol/l) increases the power of the study.
Moreover most of trials with hard endpoints used a com-
bination of B vitamins and most trials used pharmacolog-
ical doses. This has the disadvantage that the results will
be difficult to translate into dietary advises. In addition,
recent research has indicated that supplementation with
5-methyl tetrahydrofolate (5-methyl-THF), the most
abundant natural folate vitamer, is safe and lowers homo-
cysteine levels [35-37]. This form of folate, in contrast to
folic acid, does not lead to circulating unmetabolized folic
acid [38]. Unmetabolized folic acid is hypothesized to
mask the hematological manifestations of a vitamin B12
deficiency, thereby predisposing subjects to irreversible
neurological damage. Stable 5-methyl-THF was not avail-
able when other intervention studies started and therefore
they all use folic acid.
Finally, definitive proof that supplementation with n-3
fatty acids and/or B-vitamins leads to reduced cardiovas-
cular disease morbidity and/or mortality remains insuffi-
cient. The currently available intervention trials have
reported that the strength of the association of homo-
cysteine with risk of cardiovascular disease is probably
weaker than was believed at the time that many of the tri-
als were initiated. For all these reasons, we proposed
introducing, in our planned trial on the effects of folates
and vitamin B, a specific arm testing the effect of n-3 fatty
acids.
High-quality trials in different types of populations and
specifically testing n-3 fatty acids and folates (with correct
allocation concealment, hard CV endpoints including
sudden cardiac death, blinding of participants and health
providers, and adequate duration) are needed to be able
to reach a conclusion.
Conclusion
The originality of the SU.FOL.OM3 study is that this trial
included supplementation with B-vitamins or n-3 fatty
acids, and stroke and myocardial infarction as hard end-
points. A more important difference between the
SU.FOL.OM3 study and the available published trials is
the dose issue and the form of folates that is tested. All tri-
als used pharmacological doses of B-vitamins and
SU.FOL.OM3 is the only one trial that tests nutritional
doses. It is also the only one to use 5-methyl THF instead
of folic acid, which is predominantly present in circula-
tion and the most abundant natural folate form. Several
secondary prevention trials will be able in the next few
years to answer the question whether a lower tHcy con-
centration through vitamin (folic acid, vitamin B6 and
B12) and n-3 fatty acids suppementation have an effect on
"hard" end points, like CHD and stroke.
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Appendix
THE SU.FOL.OM3 STUDY GROUP AND KEY 
PERSONNEL
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France
Principal investigators: Pilar GALAN, Jacques BLACHER,
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Data Management: Sandrine BERTRAIS, Fréderik CASSOR,
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- Ecole de Santé Publique, Faculté de Médecine, Univer-
sité de Nancy
Principal investigators: Serge BRIANCONPage 7 of 9
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